Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.

[1]  C. Redfern,et al.  Rucaparib or Physician's Choice in Metastatic Prostate Cancer. , 2023, The New England journal of medicine.

[2]  Hsin-Ta Wu,et al.  A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes , 2022, Nature Cancer.

[3]  W. Abida,et al.  A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration , 2022, Current oncology.

[4]  A. Armstrong,et al.  PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). , 2022, Journal of Clinical Oncology.

[5]  H. Scher,et al.  Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. , 2022, The Lancet. Oncology.

[6]  F. Saad,et al.  Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. , 2021, The Lancet. Oncology.

[7]  S. Srinivas,et al.  Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) , 2021, BMC Cancer.

[8]  K. Nathanson,et al.  Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. Soubeyran,et al.  Prostate cancer and PARP inhibitors: progress and challenges , 2021, Journal of Hematology & Oncology.

[10]  M. Wirth,et al.  Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. , 2021, European urology.

[11]  C. Higano,et al.  Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[13]  P. Kantoff,et al.  Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. , 2020, JCO precision oncology.

[14]  F. Feng,et al.  Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study , 2020, Clinical Cancer Research.

[15]  R. Coleman,et al.  Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors , 2019, International Journal of Gynecological Cancer.

[16]  Anjali D. Zimmer,et al.  Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines. , 2019, The Journal of molecular diagnostics : JMD.

[17]  M. Loda,et al.  Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. , 2019, European urology.

[18]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[19]  Doron Lipson,et al.  Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA , 2018, The Journal of molecular diagnostics : JMD.

[20]  H. Swaisland,et al.  In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib , 2017, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  Beth Crawford,et al.  Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients , 2017, Breast Cancer Research and Treatment.

[22]  A. Oza,et al.  A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors , 2017, Clinical Cancer Research.

[23]  K. Baggerly,et al.  Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers , 2015, Clinical Cancer Research.

[24]  D. Dearnaley,et al.  PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate , 2015, European urology.

[25]  S. D. de Morais,et al.  Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). , 2013, Journal of pharmaceutical sciences.

[26]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[27]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.